Sarepta Therapeutics's ROE % for the quarter that ended in Mar. 2026 was 100.07%. Sarepta Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 1.52.
Sarepta Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 65.84%.
Sarepta Therapeutics ROE % Adjusted to Book Value Related Terms
Sarepta Therapeutics ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Sarepta Therapeutics's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sarepta Therapeutics ROE % Adjusted to Book Value Chart
LTS:0L35 vs ZYME, BCAX, INVA: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Sarepta Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sarepta Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Sarepta Therapeutics's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 65.84% mean?
Sarepta Therapeutics (LTS:0L35) has a ROE % Adjusted to Book Value of 65.84% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Sarepta Therapeutics and its competitors.
Is Sarepta Therapeutics' ROE % Adjusted to Book Value too high?
Sarepta Therapeutics' current ROE % Adjusted to Book Value is 65.84%. Overall, Sarepta Therapeutics has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' ROE % Adjusted to Book Value compare to ZYME and BCAX?
Sarepta Therapeutics' ROE % Adjusted to Book Value of 65.84% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Sarepta Therapeutics and its competitors. Sarepta Therapeutics's current ROE % Adjusted to Book Value is 65.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (LTS:0L35) is currently considered Possible Value Trap. The stock's GF Value™ is $131.71, compared to a current price of $19.09 — trading 85.5% below its estimated fair value. The current ROE % Adjusted to Book Value is 65.84%. Sarepta Therapeutics' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Sarepta Therapeutics (LTS:0L35), the current ROE % Adjusted to Book Value is 65.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sarepta Therapeutics (LTS:0L35) Overvalued in 2026?
Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued.
The current stock price of $19.09 is trading 85.5% below its estimated GF Value™ of $131.71.
GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.
Key valuation signals for LTS:0L35:
ROE % Adjusted to Book Value: 65.84%
GF Value™: $131.71 vs. price of $19.09 (85.5% below fair value)
No single metric tells the full story. See the LTS:0L35 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
51GF Score
Get the complete analysis for LTS:0L35
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0L35 has been successfully added to your 
